Overview

Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects

Status:
COMPLETED
Trial end date:
2021-04-12
Target enrollment:
Participant gender:
Summary
This is a single-dose and multiple doses study to assess the Pharmacokinetics (PK) of rilzabrutinib as well as to evaluate the tolerability of rilzabrutinib in Japanese and Caucasian Healthy Male and Female subjects.
Phase:
PHASE1
Details
Lead Sponsor:
Principia Biopharma, a Sanofi Company